AI Spots Appetite Paradox in Unapproved Retatrutide Posts — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Penn researchers analyzed approximately 150,000 Reddit posts and comments from around 40,000 users, identifying roughly 14,000 who claimed to have taken an unapproved version of retatrutide, a GLP-1 weight-loss drug currently in Phase 3 trials and not yet FDA-approved.
- Published in JAMA Network Open, the study found that increased appetite — not the nausea and gastrointestinal issues documented in Phase 2 trials — was the most commonly reported classifiable symptom among users discussing gray-market retatrutide.
- Compared with earlier Penn Reddit analyses of semaglutide and tirzepatide, retatrutide discussions contained proportionally more reports of appetite changes, sleep disturbances, elevated heart rate, and muscle-related symptoms, and proportionally fewer digestive complaints.
- Retatrutide activates three hormone receptors involved in blood sugar and appetite regulation, versus one for semaglutide and two for tirzepatide, which researchers said could produce a distinct side-effect profile — though they also noted the gray-market population likely differs from clinical trial participants.
- The researchers cautioned that products purchased outside regulated channels may differ in ingredients, purity, and dosage, and that Reddit self-reports cannot establish causation; the stated goal is to generate hypotheses that other teams can test against independent datasets.
- The same Penn team previously used AI to flag menstrual irregularity reports among semaglutide and tirzepatide users on Reddit — a finding later corroborated in a separate study using FDA adverse-event data published in Obstetrics & Gynecology.
- Co-author Jena Shaw Tronieri disclosed an investigator-initiated grant from Novo Nordisk and consulting fees from Currax Pharmaceuticals; first author Neil Sehgal and senior author Sharath Chandra Guntuku lead Penn's Computational Social Listening Lab.
Why it matters: Retatrutide works through a novel triple-receptor mechanism unlike approved GLP-1 drugs, yet gray-market users self-report increased appetite as the top symptom — opposite of what Phase 2 trials documented. Researchers frame the analysis as hypothesis-generating, not proof, but the same Penn methodology previously surfaced menstrual irregularity signals later confirmed in FDA adverse-event data.
Ask SkimNews
